These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9621275)

  • 1. Drug-associated facial dyskinesias--a study of 238 patients.
    Mauriello JA; Carbonaro P; Dhillon S; Leone T; Franklin M
    J Neuroophthalmol; 1998 Jun; 18(2):153-7. PubMed ID: 9621275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, placebo-controlled, crossover clinical trial of super blue-green algae in patients with essential blepharospasm or Meige syndrome.
    Vitale S; Miller NR; Mejico LJ; Perry JD; Medura M; Freitag SK; Girkin C
    Am J Ophthalmol; 2004 Jul; 138(1):18-32. PubMed ID: 15234278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum A toxin treatment for blepharospasm and Meige syndrome: report of 100 patients.
    Poungvarin N; Devahastin V; Chaisevikul R; Prayoonwiwat N; Viriyavejakul A
    J Med Assoc Thai; 1997 Jan; 80(1):1-8. PubMed ID: 9078810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Local injection treatment with botulinum toxin A in blepharospasm, Meige syndrome and hemifacial spasm. Observations in 106 patients].
    Ceballos-Baumann AO; Gasser T; Dengler R; Oertel WH
    Nervenarzt; 1990 Oct; 61(10):604-10. PubMed ID: 2274092
    [No Abstract]   [Full Text] [Related]  

  • 5. Botulinum toxin for neurological disorders in a movement disorders clinic in Singapore.
    Tan AK
    Singapore Med J; 1998 Sep; 39(9):403-5. PubMed ID: 9885719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.
    Van Gerpen JA; Kumar N; Bower JH; Weigand S; Ahlskog JE
    Arch Neurol; 2006 Feb; 63(2):205-9. PubMed ID: 16476808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term enhancement of botulinum toxin injections by upper-eyelid surgery in 14 patients with facial dyskinesias.
    Mauriello JA; Keswani R; Franklin M
    Arch Otolaryngol Head Neck Surg; 1999 Jun; 125(6):627-31. PubMed ID: 10367918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial.
    Truong D; Comella C; Fernandez HH; Ondo WG;
    Parkinsonism Relat Disord; 2008; 14(5):407-14. PubMed ID: 18325821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of aberrant facial nerve regeneration with botulinum toxin A.
    Chua CN; Quhill F; Jones E; Voon LW; Ahad M; Rowson N
    Orbit; 2004 Dec; 23(4):213-8. PubMed ID: 15590522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Supramaximal doses of botulinum toxin for refractory blepharospasm.
    Levy RL; Berman D; Parikh M; Miller NR
    Ophthalmology; 2006 Sep; 113(9):1665-8. PubMed ID: 16828511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tardive blepharospasm.
    Sachdev P
    Mov Disord; 1998 Nov; 13(6):947-51. PubMed ID: 9827620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
    Badarny S; Susel Z; Honigman S
    Isr Med Assoc J; 2008 Jul; 10(7):520-2. PubMed ID: 18751631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of botulinum toxin in Meige's disease.
    Maurri S; Brogelli S; Alfieri G; Barontini F
    Riv Neurol; 1988; 58(6):245-8. PubMed ID: 3247565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years.
    Mauriello JA; Dhillon S; Leone T; Pakeman B; Mostafavi R; Yepez MC
    Br J Ophthalmol; 1996 Dec; 80(12):1073-6. PubMed ID: 9059273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin treatment of hemifacial spasm and blepharospasm: objective response evaluation.
    Thussu A; Barman CR; Prabhakar S
    Neurol India; 1999 Sep; 47(3):206-9. PubMed ID: 10514580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blepharospasm and hemifacial spasm: a protocol for titration of botulinum toxin dose to the individual patient and for the management of refractory cases.
    Ortisi E; Henderson HW; Bunce C; Xing W; Collin JR
    Eye (Lond); 2006 Aug; 20(8):916-22. PubMed ID: 16531977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Results of long term treatment of essential blepharospasm and facial hemispasm with botulinum toxin A].
    Ziak P
    Cesk Slov Oftalmol; 2004 Jan; 60(1):37-44. PubMed ID: 15011305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural history of treatment of facial dyskinesias with botulinum toxin: a study of 50 consecutive patients over seven years.
    Mauriello JA; Aljian J
    Br J Ophthalmol; 1991 Dec; 75(12):737-9. PubMed ID: 1768664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of jaw-closing and jaw-opening idiopathic oromandibular dystonia.
    Singer C; Papapetropoulos S
    Parkinsonism Relat Disord; 2006 Mar; 12(2):115-8. PubMed ID: 16271495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.